In this issue:
8 weeks of ledipasvir/sofosbuvir: high efficacy in GT1 HCV
Proanthocyanidin blocks HBV entry, regardless of genotype
Novel cyclosporin-related compounds inhibit HBV entry
A novel strategy for pan-genotypic HCV protection?
Novel data on how HBeAg promotes HBV persistence
HCV resistance data in ledipasvir/ sofosbuvir treatment failures
Sofosbuvir + weight-based ribavirin: high SVR12 in GT2 HCV
DAAs: high efficacy in renal transplant recipients
Assessing NK cell responsiveness to IFNα in HCV
The US burden of chronic liver disease of various aetiologies
Please login below to download this issue (PDF)